ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
ASCO-GU – Flare hits an “undruggable” target
But biomarker enrichment and toxicity remain key for FX-909.
ASCO-GU 2026 – gauging Welireg’s double win
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ASCO-GU 2026 – Protara gets that sinking feeling
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
ASCO-GU 2026 – casdatifan starts to look competitive
Median PFS appears to back earlier response rate promise.
MHNCS 2026 – J&J and Bicara face off
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ASCO-GU 2026 – late-breakers in focus
Welireg, Padcev, and a surprise fillip for Flare.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
